Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 606

Sort by

Sort Order Select

Journal Articles

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

Marco Rossi, MD, Emanuela Altomare, PhD, Cirino Botta, MD, Maria Eugenia Gallo Cantafio, Marco Gaspari, Domenico Taverna, Sarvide Sarai, Daniele Caracciolo, MD, Paola Critelli, MD, Francesco Conforti, Maria Teresa Di Martino, PhD, Bruno Paiva, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 505.

https://doi.org/10.1182/blood-2019-122429

Published: 2019

Journal Articles

Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease

Martina Chiu, PhD, Denise Toscani, PhD, Emanuela Vicario, PhD, Roberta Andreoli, PhD, Giuseppe Taurino, MS, Valentina Marchica, MS, Paola Storti, PhD, Massimiliano Bianchi, PhD, Ovidio Bussolati, MD PhD, Nicola Giuliani

Blood (2019) 134 (Supplement_1): 4339.

https://doi.org/10.1182/blood-2019-128034

Published: 2019

Journal Articles

Ixazomib Modulates Bone Remodeling and Actives Sonic Hedgehog Pathways

Daniele Tibullo, PhD, Anna Longo, PhD, Alessandra Romano, MD PhD, Alessandro Barbato, Cesarina Giallongo, PhD, Michelino Di Rosa, PhD, Carmelina Daniela Anfuso, Gabriella Lupo, Concetta Conticello, MD, Nunzio Vicario, PhD, Rosario Gulino, PhD, Rosalba Parenti, PhD, Giuseppe A. Palumbo, MD PhD, Giovanni Li Volti, MD PhD, Francesco Di Raimondo, MD

Blood (2019) 134 (Supplement_1): 4345.

https://doi.org/10.1182/blood-2019-129927

Published: 2019

Journal Articles

Computational Analysis Model Applied to Spanish Gaucher Registry Data

Marcio M Andrade-Campos, MD PhD, Laura Lopez de Frutos, PhD, Jorge J Cebolla, MSc, Blanca Medrano-Engay, PhD, Mercedes Roca-Espiau, PhD, Beatriz Gomez-Barrera, David Iniguez, Pilar Giraldo, PhD

Blood (2019) 134 (Supplement_1): 2323.

https://doi.org/10.1182/blood-2019-122347

Published: 2019

Journal Articles

Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma

Jing Fu, PhD, Shirong Li, PhD, Chen Yang, Lewis M Brown, PhD, Stephen J Weiss, MD PhD, Charles G Drake, MD PhD, Markus Y. Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 3072.

https://doi.org/10.1182/blood-2019-129177

Published: 2019

Journal Articles

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Mehmet Kemal Samur, PhD, Anil Aktas Samur, PhD, Tessa Han, Marco Roncador, MD MSc, Mariateresa Fulciniti, PhD, Raphael Szalat, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Anjan Thakurta, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, MD PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3055.

https://doi.org/10.1182/blood-2019-128521

Published: 2019

Journal Articles

Prognostic Value of Diffusion-Weighted Magnetic Resonance Imaging in Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation

Elena Fernández-Poveda, Valentin Cabañas, MD, Maria José Moreno, Miguel Blanquer Blanquer, MD PhD, José M Moraleda, MD

Blood (2019) 134 (Supplement_1): 3146.

https://doi.org/10.1182/blood-2019-130804

Published: 2019

Journal Articles

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Stephen J Noga, MD PhD, Robert M. Rifkin, MD, Sudhir Manda, MD, Ruemu Ejedafeta Birhiray, MD, Roger M. Lyons, MD, Presley Whidden, Robert L. Schlossman, MD, Bingxia Wang, PhD, Ralph V. Boccia, MD

Blood (2019) 134 (Supplement_1): 3168.

https://doi.org/10.1182/blood-2019-124784

Published: 2019

Journal Articles

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Kenta Mukaihara, MD PhD, Mattia D'Agostino, MD, Cristina Panaroni, PhD, Keertik Fulzele, PhD, Tomoaki Mori, MD PhD, Ka Tat Siu, PhD, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2019) 134 (Supplement_1): 4382.

https://doi.org/10.1182/blood-2019-130462

Published: 2019

Journal Articles

Glycosylationof Immunoglobulins Determine Bone Loss in Multiple Myeloma

Marita Westhrin, Vlado Kovcic, Albert Bondt, Stephanie Holst, Zejian Zhang, Anders Sundan, PhD, Tobias S. Slørdahl, Anders Waage, MD PhD, Manfred Wuhrer, Therese Standal

Blood (2019) 134 (Supplement_1): 4324.

https://doi.org/10.1182/blood-2019-122542

Published: 2019

Journal Articles

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Edward Simpson, PhD, Judith L Anderson, BS, Xiang-Qun Xie, PhDMD,MBA, Yunlong Liu, PhD, John Chirgwin, PhD, G. David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4391.

https://doi.org/10.1182/blood-2019-131865

Published: 2019

Journal Articles

Myc and Bet Proteins Orchestrate the Early Regulatory Genome Changes Required for Osteoclast Lineage Commitment

Valentina S Caputo, Nikolaos Trasanidis, Xiaolin Xiao, Mark E Robinson, Alexia Katsarou, Kanagaraju Ponnusamy, Aristeidis Chaidos, Holger W Auner, MD PhD, Irene Roberts, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 4329.

https://doi.org/10.1182/blood-2019-125047

Published: 2019

Journal Articles

Complement C3a Not C4a Activates Osteoclasts By Regulating the PI3K/PDK1/SGK3 Pathway in Patients with Multiple Myeloma

Rong Fu, Jr., PhD, Fengjuan Jiang, Hui Liu, Zhaoyun Liu, Siyang Yan, Jin Chen, Zonghong Shao, MD, Qing Shao

Blood (2019) 134 (Supplement_1): 4416.

https://doi.org/10.1182/blood-2019-127022

Published: 2019

Journal Articles

Thrombin: A Driver or Attenuator of Bone Disease on Hemophilia?

Galen Goldscheitter, BS, BA, Robert Klein, MD, Jason A Taylor, MD PhD

Blood (2019) 134 (Supplement_1): 4916.

https://doi.org/10.1182/blood-2019-130698

Published: 2019

Journal Articles

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

Shoshana Revel-Vilk, MD, Tama Dinur, PhD, Majdolen Istaiti, Dafna Frydman, DMV, Michal Becker-Cohen, MSc, Ari Zimran, MD

Blood (2019) 134 (Supplement_1): 4712.

https://doi.org/10.1182/blood-2019-123000

Published: 2019

Journal Articles

Biomarker Response to Oral Eliglustat in Adults with Gaucher Disease Type 1: Results from 4 Completed Clinical Trials

Neal J Weinreb, MD, Timothy M Cox, MD, Pramod K. Mistry, MD PhD FRCP, Joel Charrow, MD, Elena Lukina, MD PhD Professor, Meredith C. Foster, ScD, M. Judith Peterschmitt, MD

Blood (2019) 134 (Supplement_1): 4859.

https://doi.org/10.1182/blood-2019-127337

Published: 2019

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Blood (2019) 134 (Supplement_1): 693.

https://doi.org/10.1182/blood-2019-125120

Published: 2019

Journal Articles

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Blood (2019) 134 (Supplement_1): 692.

https://doi.org/10.1182/blood-2019-123143

Published: 2019

Journal Articles

Structural Basis of Vitamin K Antagonism

Weikai Li, PhD, Shixuan Liu, Shuang Li

Blood (2019) 134 (Supplement_1): 482.

https://doi.org/10.1182/blood-2019-127324

Published: 2019

Journal Articles

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Poornima Ramadas, MBBS, Ajay Tambe, MBBS, Mijung Lee, MD

Blood (2019) 134 (Supplement_1): 5463.

https://doi.org/10.1182/blood-2019-131577

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease

Ixazomib Modulates Bone Remodeling and Actives Sonic Hedgehog Pathways

Computational Analysis Model Applied to Spanish Gaucher Registry Data

Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Prognostic Value of Diffusion-Weighted Magnetic Resonance Imaging in Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Glycosylationof Immunoglobulins Determine Bone Loss in Multiple Myeloma

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Myc and Bet Proteins Orchestrate the Early Regulatory Genome Changes Required for Osteoclast Lineage Commitment

Complement C3a Not C4a Activates Osteoclasts By Regulating the PI3K/PDK1/SGK3 Pathway in Patients with Multiple Myeloma

Thrombin: A Driver or Attenuator of Bone Disease on Hemophilia?

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

Biomarker Response to Oral Eliglustat in Adults with Gaucher Disease Type 1: Results from 4 Completed Clinical Trials

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Structural Basis of Vitamin K Antagonism

Amyloidosis and Plasma Cell Dyscrasias: A Single Institution Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only